| Catalog No | Package | Original Price | Price | Inventory | Quantity | Operating |
|---|---|---|---|---|---|---|
| BP5089-5mg | 5mg | $490.00 | Sign in |
|
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Dihydrobaicalin (CAS No.: 56226-98-3) is an important natural flavonoid glycoside, mainly derived from Scutellaria lateriflora L.). As a traditional Chinese medicinal material, Scutellaria baicalensis has attracted attention for its abundance of flavonoids and possesses broad pharmacological activity. As one of the active ingredients in Scutellaria baicalensis, dihydrobaicalin has shown significant potential in recent years in the treatment of diseases such as liver fibrosis. Liver fibrosis is a key pathological process in which various chronic liver diseases progress to cirrhosis and even liver cancer. Its pathological mechanism is complex, involving multiple cytokines and signaling pathways. Given the limited effective clinical drugs for liver fibrosis, natural products—especially flavonoids—have become research hotspots due to their multi-target regulation and low toxicity side effects. This paper will systematically review the chemical structure and physicochemical properties of dihydrobaicalin, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation and pharmacokinetic characteristics, and finally explore its clinical application prospects and future development directions.
Dihydrobaicalin is a type of flavonoid glycoside with a molecular formula of C21H20O11 and a molecular weight of 448.38. Its structural feature is a dihydrogenated derivative of the flavonoid nucleus, attached to the glycoside part. Specifically, the flavonoid structure of dihydrobaicalin contains multiple hydroxyl groups, giving it excellent hydrophilicity and biological activity. In terms of physicochemical properties, its LogP value is 0.7313, indicating moderate lipid solubility, which facilitates cell membrane penetration without being overly hydrophobic. The polar surface area (TPSA) is 183.21 Ų, indicating strong polarity that facilitates interactions with biological macromolecules such as proteins. The water solubility test value was 2.7816, indicating good solubility in water and suitable for oral administration. The blood-brain barrier has low penetration capacity, suggesting a low risk of side effects in the central nervous system. The hERG channel inhibition test was negative, indicating a lower risk of cardiotoxicity. The Ames-induced mutagenic test result was 0.0, indicating extremely low genotoxicity risk and good safety.
Dihydrobaicalin mainly comes from plants of the Scutellaria genus, especially Scutellaria lateriflora L., which is widely used in traditional medicine for clearing heat and detoxifying, anti-inflammatory, and treating liver diseases. Scutellaria baicalensis is rich in flavonoids. Dihydrobaicalin, as an important component, may not be as abundant as baicalin and other major components, but its unique biological activity makes it a key research focus.
The extraction method typically uses solvent extraction combined with chromatography separation technology. Common extraction processes include:
In recent years, new technologies such as supercritical fluid extraction and microwave-assisted extraction have also been applied to improve extraction efficiency and purity, reduce the use of organic solvents, and align with green chemistry principles.
Dihydrobaicalin shows significant activity in various pharmacological effects, especially in the field of liver fibrosis research. Liver fibrosis is the liver's response to chronic injury, manifested as abnormal deposition of extracellular matrix (ECM) that leads to liver dysfunction. Dihydrobaicalin regulates liver fibrosis through multiple targets and pathways, with specific pharmacological activities including:
Anti-liver fibrosis effect
Animal models and cell experiments have shown that dihydrobaicalin can significantly inhibit the activation of hepatic stellate cells (HSCs), reduce collagen (COL1A1) deposition, and improve liver tissue structure. Its mechanism of action involves regulating the balance of matrix metalloproteinase (MMP2) and its inhibitor TIMP1, promoting ECM degradation, and inhibiting fibrotic progression.
Anti-inflammatory effects
Dihydrobaicalin can inhibit the expression of pro-inflammatory cytokines such as transforming growth factor β1 (TGFB1), alleviate hepatic inflammatory responses, and block the inflammatory initiation of liver fibrosis.
Antioxidant effects
Its multihydroxyl structure provides excellent free radical scavenging ability, reducing oxidative stress damage to liver cells and protecting liver function.
Anti-tumor potential
Preliminary studies show that dihydrobaicalin inhibits proliferation and induces apoptosis in certain liver cancer cells, suggesting its potential role in interventions transitioning from liver fibrosis to liver cancer.
In addition, dihydrobaicalin has also been reported in neuroprotective and antibacterial aspects, but the related mechanisms require further clarification.
The anti-fibrotic effects of dihydrobaicalin involve various molecular targets, mainly including:
MMP2 (matrix metalloproteinase 2)
MMP2 is an important enzyme for ECM degradation. Dihydrobaicalin promotes fibrotic tissue remodeling and reduces collagen deposition by regulating MMP2 expression and activity.
TGFB1 (Transforming Growth Factor β1)
TGFB1 is a key pro-fibrotic factor in liver fibrosis, activating hepatic stellate cells and promoting collagen synthesis. Dihydrobaicalin inhibits the TGFB1 signaling pathway, blocking fibrotic signaling.
ACTA2 (α-smooth muscle actin)
ACTA2 is a marker for activating hepatic stellate cells. Dihydrobaicalin inhibits the myofibroblast phenotype of HSC by downregulating ACTA2 expression, thereby reducing fibrosis.
COL1A1 (type I collagen α1 chain)
COL1A1 is the main collagen component in fibrotic tissues; dihydrobaicalin inhibits its gene expression and reduces collagen deposition.
TIMP1 (matrix metalloproteinase tissue inhibitor factor 1)
TIMP1 inhibits MMP activity and promotes ECM accumulation. Dihydrobaicalin regulates TIMP1 expression, restores the MMPs/TIMPs balance, and promotes fiber tissue degradation.
Through the synergistic regulation of these targets, dihydrobaicalin effectively blocks the onset and progression of liver fibrosis. In addition, its anti-inflammatory and antioxidant effects further help improve the liver microenvironment and promote liver cell repair.
Druggability is an important indicator for evaluating the development potential of natural products. The molecular weight of dihydrobaicalin is 448.38, meeting the molecular weight requirements of the Lipinski rule. Its LogP value of 0.7313 indicates moderate lipid solubility, which is beneficial for drug absorption and distribution. A high TPSA value (183.21 Ų) suggests strong polarity, which may affect cell membrane permeability but also helps bind to water-soluble targets.
It has good water solubility, making it suitable for the development of oral formulations. The blood-brain barrier has low penetration capacity, reducing the risk of central nervous system side effects. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames test result was 0, indicating no significant genotoxicity and relatively high safety.
In terms of pharmacokinetics, current research is relatively limited. Preliminary in vivo experiments indicate that dihydrobaicalin is well absorbed orally, but its bioavailability is limited by the hydrolysis and metabolism of glycoside structures. In the liver, it may be metabolized enzymatically into active or inactive metabolites. In the future, systematic in vivo pharmacokinetic studies are needed, including absorption, distribution, metabolism, and excretion (ADME) characteristics and drug interaction assessment.
As liver fibrosis is the common pathological basis of various chronic liver diseases, there is a lack of specific therapeutic drugs. Dihydrobaicalin, with its multi-target regulation and good safety profile, has good clinical application potential. In the future, clinical translation can be approached from the following aspects:
New drug development
Through structural optimization and formulation improvements, its bioavailability and targeting are enhanced, and oral or injectable formulations are developed to meet clinical needs.
Combination medication strategies
When used in combination with existing antifibrotic or hepatoprotective drugs, it achieves synergistic effects, improves efficacy, and reduces the dosage and side effects of single drugs.
Indication expansion
Beyond liver fibrosis, explore its potential in other fibrotic diseases (such as pulmonary fibrosis and renal fibrosis) and adjuvant therapy for liver cancer.
Clinical trials
Conduct systematic preclinical safety evaluations and Phase I/II clinical trials to verify efficacy and safety, and promote clinical application.
Mechanism research deepened
Using modern molecular biology techniques, further elucidates its mechanism of action and target network to guide precise medication.
Dihydrobaicalin, as an important flavonoid glycoside compound in Scutellaria baiqin, has become a research hotspot in the field of natural product pharmacology due to its remarkable anti-fibrotic activity and good safety. Its multi-target, multi-pathway regulation mechanism provides both theoretical and practical basis for the development of novel anti-fibrotic drugs. Although research on its pharmacokinetics and clinical applications is still in its early stages, with continuous advances in extraction and purification technology, drug design, and clinical research, dihydrobaicalin is expected to become an important candidate drug for the treatment of liver fibrosis and related diseases. Future research should focus on improving its bioavailability, clarifying its mechanism of action, and evaluating its safety, promoting its clinical application and providing new treatment options for liver disease patients.
